Karl Reineke

USPTO Granted Patents = 9 (Patent Applications = 2)

CIPO Patents = 4

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Niskayuna, NY (US) (2015 - 2018)
Placitas, NM (US) (2018 - 2021)

Company Filing History:

4 out of 6

Corbus Pharmaceuticals, Inc.

Years Active: 2015-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11052066 - Ultrapure tetrahydrocannabinol-11-oic acids (2021-07-06),

2. 10369131 - Ultrapure tetrahydrocannabinol-11-oic acids (2019-08-06),

3. 10154986 - Ultrapure tetrahydrocannabinol-11-oic acids (2018-12-18),

4. 10111893 - Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment (2018-10-30),

5. 10085964 - Ultrapure tetrahydrocannabinol-11-oic acids (2018-10-02),

6. 9920045 - Solid state forms of a PDE10 inhibitor (2018-03-20),

7. 9650368 - Processes and intermediates for the preparation of a PDE10 inhibitor (2017-05-16),

8. 9597334 - Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment (2017-03-21),

9. 9187509 - Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment (2015-11-17),

Title: Innovations in Medicinal Chemistry: The Contributions of Karl E. Reineke

Introduction: Karl E. Reineke, based in Placitas, NM, is an accomplished inventor known for his significant contributions to the field of medicinal chemistry. With a total of four patents to his name, Reineke is dedicated to advancing medical science through innovative approaches to treatment and prevention of various diseases.

Latest Patents: Among his latest innovations are the patents related to ultrapure tetrahydrocannabinol-11-oic acids. These applications focus on the synthesis, pharmaceutical compositions, and methodologies for utilizing ultrapure ajulemic acid. The primary aim of these inventions is to address inflammation, pain, and fibrotic diseases such as scleroderma, systemic sclerosis, liver cirrhosis, and chronic kidney disease, among others. Reineke's work has the potential to transform therapeutic options for patients suffering from these challenging conditions.

Career Highlights: Karl E. Reineke has made noteworthy strides in the pharmaceutical industry, primarily through his role at Corbus Pharmaceuticals, Inc. There, he has worked on pioneering technologies that bridge the gap between medicinal chemistry and practical treatment applications. His patent portfolio illustrates his commitment to innovation in drug development.

Collaborations: In addition to his individual work, Reineke collaborates with esteemed colleagues such as Mark Tepper and Dean A. Frey. These partnerships enhance the depth and breadth of research and development initiatives at Corbus Pharmaceuticals, enabling the team to explore new horizons in medicinal advancements.

Conclusion: Karl E. Reineke's contributions to the field of medicinal chemistry exemplify the spirit of innovation and dedication to improving healthcare outcomes. His latest patents, particularly in the area of ultrapure tetrahydrocannabinol-11-oic acids, signify a promising future for patients dealing with serious medical challenges. Through his work and collaborations, Reineke continues to push the boundaries of what is possible in the realm of medicinal compounds.

This text is generated by artificial intelligence and may not be accurate.